Could a daily pill tame advanced breast cancer? new trial tests oral paclitaxel
NCT ID NCT07602907
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an oral form of the chemotherapy drug paclitaxel, taken daily or three times a week, for people with advanced HER2-negative breast cancer. The study first finds the best dose of the oral pill alone, then combines it with the immunotherapy toripalimab to see if it can delay cancer growth. About 44 adults who have already tried other treatments will participate, with regular checkups to monitor safety and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel oral solution and toripalimab (an immunotherapy drug)
What this could lead to
If successful, this could offer a more convenient oral chemotherapy option and a new combination therapy to slow cancer growth in advanced HER2-negative breast cancer.
What could go wrong
This is an early Phase 2 trial with only 44 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes compared to existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••